Education
About Us
Working with TipRanks
Follow Us
IHI - ETF AI Analysis
Top Page
iShares U.S. Medical Devices ETF (IHI)
Rating:74Outperform
Price Target:―
Positive Factors
Focused Exposure to Medical Devices
The ETF gives targeted access to U.S. medical device companies, which operate in a specialized and often resilient area of health care.
Large, Established Holdings
Many of the top positions are well-known, sizable health care companies, which can offer more stability than smaller, less proven firms.
Meaningful Fund Size
With several billion dollars in assets, the ETF is large enough that it is likely to trade relatively smoothly for most everyday investors.
Negative Factors
Recent Weak Performance
The fund has shown negative returns over the past month, three months, and year to date, signaling recent weakness in its segment of the market.
Heavy Concentration in a Few Stocks
A small number of holdings make up a large share of the portfolio, which increases the impact that any one company’s poor performance can have on the ETF.
Narrow Sector and Geographic Focus
Almost all of the ETF’s assets are in U.S. health care stocks, so it offers little diversification across other sectors or regions.
IHI vs. SPDR S&P 500 ETF (SPY)
AUM3.50B
RegionNorth America
Expense Ratio0.38%
Beta0.69
IssueriShares
Inception DateMay 01, 2006
Dividend Yield0.37%
Asset ClassEquity
Index TrackedDJ US Select / Medical Equipment
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,944,820
30 Day Avg. Volume1,694,702
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
72.64Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IHI Summary
The iShares U.S. Medical Devices ETF (IHI) tracks the DJ US Select / Medical Equipment index, focusing on U.S. companies that make medical devices and equipment used in diagnostics, surgery, and patient care. It holds well-known names like Abbott Laboratories and Intuitive Surgical, giving investors a simple way to invest in the growth of healthcare technology without having to pick individual stocks. Someone might consider IHI for long-term growth and sector diversification within healthcare. A key risk is that it is heavily concentrated in medical device companies, so it can rise or fall sharply with this specific part of the market.
How much will it cost me?The iShares U.S. Medical Devices ETF (IHI) has an expense ratio of 0.38%, which means you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically involves more specialized management compared to broad-market passive funds.
What would affect this ETF?The iShares U.S. Medical Devices ETF (IHI) could benefit from growing demand for advanced healthcare solutions and technological innovations in medical devices, driven by an aging population and increased focus on personalized medicine. However, potential risks include regulatory changes, pricing pressures, and economic downturns that may impact healthcare spending, as well as competition among top holdings like Abbott Laboratories and Intuitive Surgical. The ETF’s focus on U.S.-based companies may also limit exposure to growth opportunities in international markets.
IHI Top 10 Holdings
IHI is very much a U.S. medical‑devices story, and a handful of big names are steering the ship. Abbott, Intuitive Surgical, and Boston Scientific have been losing steam lately, acting as a drag on the fund despite solid long-term narratives. Offsetting some of that weakness, steadier names like Becton Dickinson, Medtronic, and ResMed have been quietly rising and helping keep performance from slipping too far. With almost everything tied to health care equipment in the U.S., the ETF is both thematically focused and relatively concentrated in a few heavyweight stocks.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Abbott Laboratories | 17.12% | $604.84M | $195.94B | -13.73% | 73 Outperform | |
| Intuitive Surgical | 15.05% | $531.66M | $172.54B | -18.42% | 78 Outperform | |
| Boston Scientific | 9.68% | $341.98M | $110.83B | -29.57% | 79 Outperform | |
| Stryker | 5.05% | $178.60M | $140.08B | -4.97% | 70 Outperform | |
| Medtronic | 4.82% | $170.43M | $127.55B | 7.20% | 80 Outperform | |
| Resmed | 4.75% | $167.71M | $36.79B | 8.40% | 76 Outperform | |
| GE Healthcare Technologies Inc | 4.65% | $164.18M | $36.61B | -12.87% | 78 Outperform | |
| Edwards Lifesciences | 4.42% | $156.06M | $44.03B | -0.42% | 79 Outperform | |
| Idexx Laboratories | 4.38% | $154.79M | $50.25B | 41.58% | 78 Outperform | |
| Becton Dickinson | 4.33% | $153.04M | $50.08B | -21.76% | 67 Neutral |
IHI Technical Analysis
Negative
―
Price Trends
61.47
Negative
61.29
Negative
61.23
Negative
Market Momentum
-1.13
Positive
35.72
Neutral
22.47
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IHI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 59.52, equal to the 50-day MA of 61.47, and equal to the 200-day MA of 61.23, indicating a bearish trend. The MACD of -1.13 indicates Positive momentum. The RSI at 35.72 is Neutral, neither overbought nor oversold. The STOCH value of 22.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IHI.
IHI Peer Comparison
Comparison Results
Performance Comparison
IHI
iShares U.S. Medical Devices ETF
57.99
-6.62
-10.25%
IBB
iShares Biotechnology ETF
―
―
―
XBI
SPDR S&P BIOTECH ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents